New

Global ETF Survey 2026 Available: How 620 Professionals Select ETFs. Access the Report →

Help us improve your experience. Please confirm your investor type:

Global ETF Survey 2026

Trackinsight Global ETF Survey 2026
GNMX

Corgi Genomics & Precision Medicine ETF

The GNMX Exchange Traded Fund (ETF) is provided by Corgi Funds. This fund is actively managed; it does not track an index. This share class generates a stream of income by distributing dividends.

Advertisement

Advertisement

$36.35
+$0.8 (+2.25%) yesterday
2:30 PM 11/06/26 Closed
1D price range
$36.32$36.35
52W price range
$23.88$39.86
YTD Perf.
+38.53%
YTD Flows
Annualized volatility
Fund AuM
€1.1M
Share class AuM
€1.1M
TTM Yield
Tracking Error
Tracking Difference
ISIN
US2189468463
TER
0.35%
Inception date
5/6/2026
Dividend policy
Compare similar ETFs
API
PerformanceMay 6, 2026 - Nov 5, 2026
-10%0%10%20%30%40%50%JUNAUGOCTJUNAUGOCT
Flows
Join for free to unlock
Data as of 09/30/26
Healthcare
97.49%
Unavailable
2.51%
Latest GNMX news

No content available for this fund

FAQ about GNMX

GNMX is an actively managed ETF that invests in the BioTech & Genomics segment.
GNMX carries a total expense ratio (TER) of 0.35%.
GNMX was introduced to the market on May 6, 2026.
Corgi Genomics & Precision Medicine ETF, GNMX, is provided by Corgi Funds. Learn more about Corgi Funds here.
GNMX oversees €1.1M in assets as of November 5, 2026.
GNMX follows a distributing dividend policy, meaning it pays out income to investors.
As of September 30, 2026, GNMX has significant geographic allocations in USA, Denmark and Netherlands.
As of September 30, 2026, GNMX focuses largely on Healthcare.
As of September 30, 2026, GNMX holds 57 positions in its portfolio, with 59.18% of assets concentrated in its top 15 holdings.
As of September 30, 2026, GNMX top three holdings include Moderna, Inc., Thermo Fisher Scientific, Inc. and Vertex Pharmaceuticals, Inc..
The base currency of GNMX is USD.
Data as of 09/30/26
Moderna, Inc.
9.96%
Thermo Fisher Scientific, Inc.
8.42%
Vertex Pharmaceuticals, Inc.
5.71%
Illumina, Inc.
4.90%
Guardant Health, Inc.
3.48%
10X Genomics, Inc.
3.48%
Iovance Biotherapeutics, Inc.
3.17%
Revolution Medicines, Inc.
3.14%
Genmab A/S
3.00%
Twist Bioscience Corp.
2.64%

Trackinsight
Essentials

A forever free toolbox for fund selection, analysis, research, and ETF portfolio construction.

Essential free account includes:
  • More fund data
  • Compare up to 3 funds
  • More screener filters
  • Edit screener columns from 100+ metrics
  • Watchlists for saving your research
  • Portfolio construction and analysis
  • Personal dashboard for live monitoring
Trackinsight Global ETF Survey 2026: ETFs' Next Act: From Access to Selection. Access the report

Advertisement

Trackinsight

About Trackinsight

Since our founding in 2016, we have been at the forefront of the industry, delivering accessible, comprehensive, and reliable tools to support the evolving needs of investors.

Over the past decade, Trackinsight has expanded its operations across six countries, serving thousands of professional investors. We’ve consistently innovated to provide cutting-edge solutions that meet the changing demands of the ETF market.

In 2024, Kepler Cheuvreux, a leading independent European financial services firm, acquired a majority stake in Trackinsight, becoming the company's principal shareholder.

This strategic partnership solidifies Trackinsight's position as a premier provider of ETF selection and analysis tools, while strengthening Kepler Cheuvreux’s commitment to becoming a leading player in the ETF sector.

Together, we are committed to offering advanced services that empower professional investors, advisors, institutions, and issuers. This new step enables us to deliver even more comprehensive and innovative technological solutions, driving ETF investing to new heights.

More about Trackinsight
© 2014-2026 Trackinsight SA. All rights reserved.
Privacy policy  |  Cookie policy  |    |  Terms of use  |  Imprint
Trackinsight